Protara Therapeutics (NASDAQ:TARA) Rating Lowered to Strong Sell at Wall Street Zen

Protara Therapeutics (NASDAQ:TARA) was downgraded by analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued on Saturday.

TARA has been the topic of several other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Friday, July 17th. HC Wainwright reissued a “buy” rating on shares of Protara Therapeutics in a research report on Wednesday, May 20th. Cantor Fitzgerald restated an “overweight” rating on shares of Protara Therapeutics in a research note on Wednesday, May 20th. JPMorgan Chase & Co. decreased their price objective on shares of Protara Therapeutics from $27.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, May 14th. Finally, Oppenheimer boosted their target price on shares of Protara Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a research note on Wednesday, May 20th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Protara Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $26.25.

Protara Therapeutics Stock Performance

Shares of NASDAQ TARA opened at $3.97 on Friday. The firm has a market cap of $234.63 million, a P/E ratio of -2.94 and a beta of 1.50. Protara Therapeutics has a 1 year low of $2.97 and a 1 year high of $7.82. The firm’s 50 day moving average price is $4.02 and its 200 day moving average price is $5.01.

Protara Therapeutics (NASDAQ:TARA) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.03). As a group, equities analysts predict that Protara Therapeutics will post -1.48 EPS for the current year.

Institutional Investors Weigh In On Protara Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. acquired a new position in Protara Therapeutics in the 2nd quarter valued at $46,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Protara Therapeutics in the second quarter valued at $53,000. Persistent Asset Partners Ltd bought a new stake in Protara Therapeutics in the fourth quarter valued at about $57,000. AXQ Capital LP bought a new position in Protara Therapeutics during the fourth quarter worth about $58,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Protara Therapeutics during the 4th quarter worth approximately $59,000. Hedge funds and other institutional investors own 38.13% of the company’s stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.